Print Page  Close Window

Investor Relations

Corporate Profile

Neothetics is a clinical-stage specialty pharmaceutical company focused on development and commercialization of therapeutics for the aesthetic market. Our current focus is on localized fat reduction and body contouring. Neothetics’ lead product candidate, LIPO-202, is a injectable treatment for undesirable, localized areas of fat with no downtime and causes no damage below the skin’s surface. Our clinical studies with LIPO-202 do not use local or systemic pain management before or after the procedure.

Stock Information
NEOT (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$0.54
Change (%) Stock is Down 0.17 (23.94%)
Volume4,231,399
Data as of 06/27/17 4:00 p.m. ET
Stock chart for: NEOT.O.  Currently trading at $0.54 with a 52 week high of $2.63 and a 52 week low of $0.65.
Recent Presentations
There are currently no items available.


Recent Publications
DateTitle
03/20/15
Download Documentation AESTHETIC TREATMENT OF CENTRAL ABDOMINAL BULGING (CAB) WITH LIPO-202 (SALMETEROL XINAFOATE FOR INJECTION)
Recent NewsMore >>
DateTitle  
06/26/17Neothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat
LIPO-202 did not show efficacy in the reduction of submental fat SAN DIEGO, June 26, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced top-line safety and efficacy results from its Phase 2 proof-of-concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat. LIPO-202 did not demonstrate improvement on any efficacy measurements or separation from placebo... 
Download PDFPrinter Friendly Version
05/11/17Neothetics Provides Business Update and Reports First Quarter 2017 Financial Results
SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today provided a business update and reported financial results for the first quarter 2017. “We are extremely pleased with the progress made during the quarter,” said Kim Kamdar, Ph.D., a member of Neothetics’ Operating Committee and Board of Directors.  “If approved, LIPO-202 could be the first non-ablative option for... 
Download PDFPrinter Friendly Version
05/04/17Neothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, announced today that it will provide a business update and release its first quarter 2017 financial results before the market opens on Thursday, May 11, 2017. To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at investors.neothetics.... 
Download PDFPrinter Friendly Version
04/05/17Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset
SAN DIEGO, April 05, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced the issuance of U.S. Patent Number 9,597,531 by the United States Patent and Trademark Office (USPTO).  This patent is directed to specific methods of using LIPO-202 and other agents for the reduction of fat accumulation. The ’531 patent is expected to expire no earlier than the fourth quarter of 2031, e... 
Download PDFPrinter Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Neothetics, Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data Provided by Thomson Reuters
Minimum 20 minutes delayed